• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

立体定向体部放射治疗免疫规划——基于一个提出的理论模型的综述

Stereotactic Body Radiotherapy Immunological Planning-A Review With a Proposed Theoretical Model.

作者信息

Swamy Kumara

机构信息

Aster CMI, Bangalore, India.

出版信息

Front Oncol. 2022 Jan 26;12:729250. doi: 10.3389/fonc.2022.729250. eCollection 2022.

DOI:10.3389/fonc.2022.729250
PMID:35155221
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8826062/
Abstract

In the stereotactic body radiotherapy (SBRT) and immunotherapy era, we are moving toward an "immunological radiation plan", i.e., radiation scheduling with abscopal effect as a vital endpoint as well. The literature review of part A enumerates the advantages of the intermediate dose of SBRT 6-10 Gy per fraction, appropriate use of dose painting, proper timing with immunotherapy, and the potential of immunoadjuvants to maximize cell kill in the irradiated lesions, found to have improved the abscopal effects. Part B summarizes part A, primarily the findings of animal trials, forming the basis of the tenets of the proposed model given in part C to realize the true abscopal potential of the SBRT tumor cell kill of the index lesions. Part C proposes a theoretical model highlighting tumor vasculature integrity as the central theme for converting "abscopal effect by chance" to "abscopal effect by design" using a harmonized combinatorial approach. The proposed model principally deals with the use of SBRT in strategizing increased cell kill in irradiated index tumors along with immunomodulators as a basis for improving the consistency of the abscopal effect. Included is the possible role of integrating immunotherapy just after SBRT, "cyclical" antiangiogenics, and immunoadjuvants/immune metabolites as abscopal effect enhancers of SBRT tumor cell kill. The proposed model suggests convergence research in adopting existing numerous SBRT abscopal enhancing strategies around the central point of sustained vascular integrity to develop decisive clinical trial protocols in the future.

摘要

在立体定向体部放射治疗(SBRT)和免疫治疗时代,我们正朝着“免疫放疗计划”迈进,即把具有远隔效应作为重要终点的放疗方案安排。A部分的文献综述列举了SBRT每次分割剂量为6 - 10 Gy的中等剂量的优势、剂量递增的合理应用、与免疫治疗的恰当时间配合以及免疫佐剂在最大化照射病灶内细胞杀伤方面的潜力,发现这些措施可改善远隔效应。B部分总结了A部分内容,主要是动物试验的结果,为C部分提出的模型原则奠定了基础,以实现SBRT对靶病灶肿瘤细胞杀伤的真正远隔效应潜力。C部分提出了一个理论模型,强调肿瘤血管系统完整性是核心主题,通过协调组合方法将“偶然的远隔效应”转化为“设计的远隔效应”。所提出的模型主要涉及利用SBRT来规划增加照射靶肿瘤内的细胞杀伤,并结合免疫调节剂作为改善远隔效应一致性的基础。其中包括在SBRT后立即整合免疫治疗、“周期性”抗血管生成药物以及免疫佐剂/免疫代谢产物作为SBRT肿瘤细胞杀伤远隔效应增强剂的可能作用。所提出的模型建议围绕持续血管完整性这一中心点,对现有的众多SBRT远隔效应增强策略进行整合研究,以制定未来决定性的临床试验方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/8826062/1dcaffc42dfb/fonc-12-729250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/8826062/7fb13a5b6c71/fonc-12-729250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/8826062/1dcaffc42dfb/fonc-12-729250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/8826062/7fb13a5b6c71/fonc-12-729250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cead/8826062/1dcaffc42dfb/fonc-12-729250-g002.jpg

相似文献

1
Stereotactic Body Radiotherapy Immunological Planning-A Review With a Proposed Theoretical Model.立体定向体部放射治疗免疫规划——基于一个提出的理论模型的综述
Front Oncol. 2022 Jan 26;12:729250. doi: 10.3389/fonc.2022.729250. eCollection 2022.
2
Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.新型立体定向体部放疗(SBRT)靶向大块肿瘤乏氧亚区的部分肿瘤照射(SBRT-PATHY):利用旁观者效应和远隔效应改善放疗结果。
Radiat Oncol. 2019 Jan 29;14(1):21. doi: 10.1186/s13014-019-1227-y.
3
Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy.在未进行免疫治疗的情况下,立体定向体部放疗治疗转移性乳腺癌中的远隔效应。
Front Oncol. 2023 Oct 6;13:1243053. doi: 10.3389/fonc.2023.1243053. eCollection 2023.
4
Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis.帕博利珠单抗治疗遗传性平滑肌瘤病和肾细胞癌失败后立体定向体部放疗两次诱发远隔效应:一项伴有基因和免疫分析的病例报告
Transl Androl Urol. 2021 Nov;10(11):4304-4312. doi: 10.21037/tau-21-644.
5
Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY).通过靶向缺氧节段的立体定向体部放疗-部分肿瘤照射(SBRT-PATHY)将免疫抑制性辐射效应转变为主要的免疫刺激性辐射效应。
Cancers (Basel). 2020 Dec 26;13(1):50. doi: 10.3390/cancers13010050.
6
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.低分割立体定向放射治疗的免疫调节:治疗意义。
Radiother Oncol. 2016 Aug;120(2):185-94. doi: 10.1016/j.radonc.2016.07.013. Epub 2016 Aug 2.
7
Abscopal effect in radioimmunotherapy.放射免疫治疗中的远隔效应。
Int Immunopharmacol. 2020 Aug;85:106663. doi: 10.1016/j.intimp.2020.106663. Epub 2020 Jun 7.
8
The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?立体定向放疗和免疫治疗的远隔效应:愚人金还是黄金国?
Clin Oncol (R Coll Radiol). 2019 Jul;31(7):432-443. doi: 10.1016/j.clon.2019.04.006. Epub 2019 Apr 17.
9
Stereotactic body radiotherapy for lung metastases in a patient with giant cell tumor of bone: a case report and literature review.立体定向体部放射治疗骨巨细胞瘤患者的肺转移:病例报告及文献复习
Ann Transl Med. 2022 Feb;10(3):156. doi: 10.21037/atm-21-6575.
10
Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues.脊柱肿瘤的精确立体定向放射治疗:机制、疗效及问题
Front Oncol. 2020 May 22;10:826. doi: 10.3389/fonc.2020.00826. eCollection 2020.

引用本文的文献

1
Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity.放疗引起的肿瘤微环境改变:代谢与免疫
Front Cell Dev Biol. 2025 Apr 28;13:1568634. doi: 10.3389/fcell.2025.1568634. eCollection 2025.
2
Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy.结合代谢组学和机器学习鉴定非小细胞肺癌患者放化疗前后的诊断和预后生物标志物。
Biomolecules. 2024 Jul 24;14(8):898. doi: 10.3390/biom14080898.
3
Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (SBRT) for breast cancer.

本文引用的文献

1
Vascular-immuno-phenotypic (VIP) model for locally advanced and oligo-metastatic cancer: A hypothesis.局部晚期和寡转移癌的血管免疫表型(VIP)模型:一个假说。
Med Hypotheses. 2021 Jul;152:110618. doi: 10.1016/j.mehy.2021.110618. Epub 2021 May 27.
2
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.带电粒子与传统放射治疗:当前作为免疫治疗搭档的意义
Cancers (Basel). 2021 Mar 23;13(6):1468. doi: 10.3390/cancers13061468.
3
Radiation and immunotherapy: emerging mechanisms of synergy.放射疗法与免疫疗法:协同作用的新机制
乳腺癌治疗进展:术前立体定向体部放疗(SBRT)治疗乳腺癌的系统评价。
Radiat Oncol. 2024 Aug 2;19(1):103. doi: 10.1186/s13014-024-02497-4.
4
Durable complete response to PET-CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review.PET-CT引导下立体定向放射治疗联合帕博利珠单抗治疗多形性肺上沟瘤的持久完全缓解:病例报告及文献综述
Clin Case Rep. 2024 Apr 5;12(4):e8633. doi: 10.1002/ccr3.8633. eCollection 2024 Apr.
5
Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model.使用脉冲立体定向体部放疗的原位癌症治疗性疫苗——一种转化模型
Vaccines (Basel). 2023 Dec 20;12(1):7. doi: 10.3390/vaccines12010007.
6
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.多组学整合模型在早期非小细胞肺癌立体定向体部放疗中的应用:MONDRIAN 研究临床试验方案。
BMC Cancer. 2023 Dec 15;23(1):1236. doi: 10.1186/s12885-023-11701-9.
7
Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers.基于肿瘤浸润淋巴细胞和基因组生物标志物个体化乳腺癌患者的放疗决策。
Breast. 2023 Oct;71:13-21. doi: 10.1016/j.breast.2023.06.010. Epub 2023 Jul 1.
8
Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.免疫治疗和放射治疗作为抗肿瘤的长效武器——具有未解决挑战的联合治疗:剂量、分割、体积、治疗顺序。
Curr Oncol. 2022 Oct 2;29(10):7388-7395. doi: 10.3390/curroncol29100580.
9
The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field.立体定向放射治疗(SBRT)与免疫系统的动态相互作用以及该领域的未来发展方向
Cancers (Basel). 2022 Sep 19;14(18):4530. doi: 10.3390/cancers14184530.
J Thorac Dis. 2020 Nov;12(11):7011-7023. doi: 10.21037/jtd-2019-cptn-07.
4
Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.放化疗联合抑制 Tregs 增强直肠癌的远隔抗肿瘤效应并抑制转移。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000826.
5
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.从放射肿瘤学角度定义寡转移疾病:ESTRO-ASTRO 共识文件。
Radiother Oncol. 2020 Jul;148:157-166. doi: 10.1016/j.radonc.2020.04.003. Epub 2020 Apr 22.
6
Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy.肿瘤微环境——癌症放射治疗的“游戏规则改变者”。
Int J Mol Sci. 2019 Jun 29;20(13):3212. doi: 10.3390/ijms20133212.
7
Abscopal Effect, From Myth to Reality: From Radiation Oncologists' Perspective.远隔效应:从神话到现实——放疗肿瘤学家视角
Cureus. 2019 Jan 9;11(1):e3860. doi: 10.7759/cureus.3860.
8
Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.新型立体定向体部放疗(SBRT)靶向大块肿瘤乏氧亚区的部分肿瘤照射(SBRT-PATHY):利用旁观者效应和远隔效应改善放疗结果。
Radiat Oncol. 2019 Jan 29;14(1):21. doi: 10.1186/s13014-019-1227-y.
9
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.放疗、免疫检查点阻断与远隔效应:关于时机、剂量和分割的批判性综述
Front Oncol. 2018 Dec 13;8:612. doi: 10.3389/fonc.2018.00612. eCollection 2018.
10
Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells.肿瘤微环境诱导自然杀伤细胞的免疫代谢重编程。
Front Immunol. 2018 Nov 8;9:2517. doi: 10.3389/fimmu.2018.02517. eCollection 2018.